Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?

Supportive Care in Cancer

Volumn 6, Issue 5, 1998, Pages 444-448

  Feld, Ronald ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antimicrobial therapy; Empiric therapy; Febrile neutropenia; Response definitions; Trial design

Indexed keywords

AZTREONAM; CLOXACILLIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SURVIVAL RATE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA; REFERENCE VALUES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0031662422     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050192     Document Type: Review

References (14)

1. Chalmers TC, Smith H, Blackburn B, et al (1981) A method for assessing the quality of a randomized controlled trial. Control Clin Trials 1:31-49
2. Cometta A, Zinner S, deBock R, et al (1995) The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445-452
3. Cometta A, Calandra T, Goya H, et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as ampiric therapy for fever in granulocytopenic patients with cancer. Animicrob Agents Chemother 40:1108-1115
4. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P (1984) Ceftazidime compared with piperacillin and tobramycin for the empiric therapy of fever in neutropenic patients with cancer. Ann Intern Med 12:834-944
5. Elliott CR, Pater JL (1988) The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clin Invest Med 11:327-330
6. Feld R (1993) Organization of clinical trials: problems, controversies, definitions and methodology related to infections in neutropenic patients. Recent Results Cancer Res 132:249-256
7. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, Pizzo PA (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
8. Hughes W, Pizzo PA, Wade JC, Armstrong D, Webb D, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 15 [Suppl 1]:S206-S215
9. Immunocompromised Host Society (1990) Consensus panel of the design analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397-401
10. Meunier F, Hughes W, Pizzo PA, et al (1993) General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. In: Beam TR, Gilbert DN, Kunin CM and The European Working Party (eds) European guidelines for the clinical evaluation of anti-infective drug products. European Society of Clinical Microbiology and Infectious Disease, pp 221-227
11. Pater JL, Wier L (1986) Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients in a critical survey. J Clin Oncol 4:346-352
12. Pizzo PA, Hathorn JW, Hiemen ZJ, Browne M, Commen J, Catton D, Gress J, Longon D, Marshall D, McKnight J, Ruben M, Skelton J, Thaler M, Wesley R (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558
13. Rolston KVI, Berkey P, Bodey GP, et al (1992) A comparism of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
14. Viscoli C, Bruzzi P, Glauser M (1995) An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile neutropenic cancer patients. Eur J Cancer [A] 31:2013-2022